T he atherogenic dyslipidemia complex consists of hypertriglyceridemia, low high-density lipoprotein, postprandial hyperlipidemia, accumulation of remnant lipoproteins, and small dense low-density lipoprotein particles. It is an important feature of insulin resistance, metabolic syndrome, and type 2 diabetes mellitus and contributes to the increased risk of atherosclerotic cardiovascular disease in individuals with these metabolic conditions. 1-3 Abnormal metabolism of triglyceride-rich lipoproteins (TRL) is a central feature of the atherogenic dyslipidemia complex, understanding of which may provide unique opportunities to reduce atherosclerotic cardiovascular disease risk in people with this condition. 1 TRL overproduction by both liver and intestine and impaired clearance of TRL particles from the circulation contribute to hypertriglyceridemia and other components of the complex. It is well established that hepatic TRL overproduction in this condition is contributed to by numerous systemic factors. Our work and that of others over the past decade have led to the appreciation that intestinal TRL production is also increased in insulin-resistant states and is subject to regulation by various systemic factors, including hormones, nutrients, nutraceuticals, and pharmaceuticals.
T he atherogenic dyslipidemia complex consists of hypertriglyceridemia, low high-density lipoprotein, postprandial hyperlipidemia, accumulation of remnant lipoproteins, and small dense low-density lipoprotein particles. It is an important feature of insulin resistance, metabolic syndrome, and type 2 diabetes mellitus and contributes to the increased risk of atherosclerotic cardiovascular disease in individuals with these metabolic conditions. [1] [2] [3] Abnormal metabolism of triglyceride-rich lipoproteins (TRL) is a central feature of the atherogenic dyslipidemia complex, understanding of which may provide unique opportunities to reduce atherosclerotic cardiovascular disease risk in people with this condition. 1 TRL overproduction by both liver and intestine and impaired clearance of TRL particles from the circulation contribute to hypertriglyceridemia and other components of the complex. It is well established that hepatic TRL overproduction in this condition is contributed to by numerous systemic factors. Our work and that of others over the past decade have led to the appreciation that intestinal TRL production is also increased in insulin-resistant states and is subject to regulation by various systemic factors, including hormones, nutrients, nutraceuticals, and pharmaceuticals. 2 Emerging evidence from animal studies suggests a role for the central nervous system (CNS) in regulating lipid homeostasis and TRL metabolism. 3, 4 When delivered directly to specific regions of the brain, several metabolites and hormones have been shown to modulate hepatic TRL secretion from the liver [5] [6] [7] [8] [9] [10] and intestine 11 in rodents. Intranasal administration of peptide hormones selectively increases their cerebrospinal fluid (CSF) concentrations in humans 12 and, thus, may serve as an effective and alternative experimental approach for targeting the CNS in humans. Using this approach, intranasal administration of insulin was shown to affect food-related activities in the CNS, cognitive performance, satiety, and food intake in humans. [13] [14] [15] We recently demonstrated that intranasal insulin suppressed hepatic glucose production independently of peripheral insulin concentration, which implies a role of CNS insulin action exerting metabolic control in the human liver. 16 In several recent studies in humans, intranasal insulin was shown to modulate liver fat content, lipolysis, and body fat, [17] [18] [19] corroborating CNS insulin action in regulation of lipid homeostasis as demonstrated in rodents. 20, 21 Intravenously delivered insulin acutely suppresses TRL production in the liver and intestine in healthy humans [22] [23] [24] ; however, it remains to be established whether intranasal insulin regulates TRL metabolism in humans.
Using stable isotope enrichment techniques, we investigated the effects of intranasal insulin on TRL production by the liver and intestine in healthy men. We selected a dose of intranasal insulin (40 IU) that has previously been demonstrated to significantly raise CSF insulin concentration 12 and suppress hepatic glucose production 16 in healthy humans. Although intranasal route of insulin provides safe, convenient, and preferential delivery to the CNS, it is associated with spillover of insulin into systemic circulation. In our previous study, intranasal administration of insulin resulted in a rapid and transient rise in plasma insulin concentration. 16 To study the putative CNS effect, in the present study as in our previous study, 16 we infused insulin intravenously for 30 minutes in the placebo arm at a dose tailored to match systemic insulin concentrations in the 2 study arms. Furthermore, the present study was performed under conditions of a pancreatic clamp to limit fluctuations of pancreatic hormones, and our study was conducted in the constant fed state to facilitate the accurate quantification of intestinal lipoprotein production rates.
Materials and Methods
Materials and Methods are available in the online-only Data Supplement.
Results

Plasma Glucose, Total Immunoreactive Insulin, and Insulin Lispro Concentrations
Nine healthy men participated in the study (Table) according to the study protocol outlined in Figure 1A . Plasma glucose concentrations during the course of the kinetic study are shown in Figure 1B . For the purpose of this study, plasma glucose was not clamped at a predetermined level, and no glucose was infused during the clamp. Plasma glucose levels were, therefore, maintained by the hourly ingestion of a liquid nutrient formula (Great Shake Plus; Hormel Health Laboratories, Austin, MN; each carton of 118 mL contains 13-g fat, 8-g protein, and 23-g carbohydrate, providing 49% of total calories from fat, 13% from protein, and 38% from carbohydrate). The volume of each hourly aliquot was calculated from total daily calorie requirement derived using the Harris-Benedict formula. Identical hourly volumes of the liquid formula were ingested in both study arms. During the early part of the kinetic study, plasma glucose levels increased from 7.6±0.5 and 7.3±0.4 mmol/L at t=0 in placebo and insulin, respectively, to 8.5±0.4 and 8.4±0.4 mmol/L at t=2 hours, followed by a gradual decline to 6.8±0.2 and 6.7±0.3 mmol/L at t=10 hours. The plasma glucose curves slightly diverged starting from t=4 hours, with levels between t=4 and 7 hours tending to be lower with intranasal insulin than that with placebo (P=0.08 ANOVA).
Plasma total immunoreactive insulin levels, determined with an assay that measures both endogenous insulin and insulin analogues, increased slightly from the beginning of the kinetic study, in a similar pattern for both study arms, and there was no significant difference between the study arms ( Figure 1C ). Plasma lispro levels ( Figure 1D) , measured with an assay with 100% specificity for lispro and negligible crossreactivity (<0.05%) to human insulin, increased slightly with intranasal insulin, indicating a modest spillover of intranasal insulin into the circulation. With intravenous lispro infusion, lispro levels in the placebo arm exhibited a similar transient rise during the first 60 minutes. At t=120 minutes, lispro levels returned to nonspecific levels of t=0 in both study arms. The systemic spillover of intranasal insulin was, therefore, closely mimicked with intravenous lispro administration.
Plasma Triglycerides, TRL Triglycerides, and Plasma Free Fatty Acids
Despite hourly ingestion of the liquid formula, triglyceride levels declined 3 hours after the start of the hourly ingestion in both treatment arms, likely due to the use of a pancreatic clamp and the transient rise in insulin levels. There were no significant differences in plasma triglyceride ( Figure 2A ) and TRL triglyceride ( Figure 2B ) between the two treatment arms. Plasma free fatty acid (FFA) levels were superimposable during the first 3 hours of the kinetic study ( Figure 2C ). However, starting from t=4 hours, plasma FFA were lower in intranasal insulin than in placebo (P=0.01, ANOVA).
TRL apoB100 and apoB48 Concentrations, Fractional Catabolic Rate, and Production Rate TRL apoB100 concentrations did not differ between treatment arms (mean concentrations during t=0-10 hour insulin 42.3±13.4 versus placebo 40.8±4.5 mg/L; P=0.54, paired t test; Figure 3A ). Fractional catabolic rate was similar between study arms (insulin 3.96±0.44 versus placebo 3.77±0.31 pools/d; P=0.87, paired t test; Figure 3B ). As a result, there was no significant difference in production rate, Figure 3D ).
Discussion
Studies in animal models have shown that TRL secretion by the liver is subject to CNS insulin regulation. In humans, intranasal insulin, presumably through its effects in the brain, exerts metabolic regulation in the liver. However, potential effects of intranasally delivered insulin on lipoprotein secretion have not previously been examined in humans. In this study, we measured TRL production by the liver and intestine in humans after intranasal insulin delivery, during a constant fed state and conditions of a pancreatic clamp. No apparent effects of intranasal insulin, administered at a dose known to significantly raise CSF insulin concentration and suppress hepatic glucose production, on TRL production were observed. Recent studies in animals suggest a role of CNS in the regulation of lipid and lipoprotein metabolism in the liver and intestine. 3, 4 When directly delivered into specific regions of the brain, several hormones and metabolites have been shown to modulate peripheral lipid metabolism. A brain-liver neuronal pathway in the control of lipid metabolism in the liver has been demonstrated for insulin in rats, 10 for neuropeptide Y in rats, 9 and for GLP-1 (glucagon-like peptide-1) in hamsters. secretion was demonstrated in hamsters. 11 Furthermore, chronic intracerebroventricular insulin in mice increased fat mass, fat cell size, and adipose tissue lipoprotein lipase expression in mice, suggesting that CNS insulin action promotes lipogenesis. 20 These studies support a role of central hormonal actions in regulating lipid metabolism via a neuronal pathway, which has not yet been rigorously examined in humans.
As direct delivery into the CNS is not feasible in humans, central actions of hormones have been studied in humans with intranasal route of administration. Intranasal administration of peptide hormones, including insulin, preferentially raises their concentrations in the CSF, 12 providing a noninvasive, safe, and alternative approach for targeting the brain. 25, 26 Using this approach, a single dose of intranasal insulin (160 IU) has been shown to modulate food-related activities in the CNS, 13 reduce food intake in men, 14 promote cognitive performance in women, 14 and decrease intake of palatable food and increase satiety in women. 15 Lower dose (40 IU) intranasal insulin was also shown to elicit effects on odor-cued reactivation of spatial memory and olfactory sensitivity in humans. 27, 28 CNS insulin action in the regulation of hepatic glucose metabolism in humans has also been a recent focus. 29 In several studies in humans, 160 IU of intranasal insulin was shown to acutely lower plasma glucose and affect peripheral insulin sensitivity. 15, 30, 31 Although these studies support a putative role of CNS insulin action in peripheral metabolic control, interpretation of the results are hampered by the fact that intranasal administration of insulin leads to spillover into systemic circulation. 16, 29 In a recent study, 16 we examined the potential role of CNS insulin action on hepatic glucose production in healthy men. We used 40 IU of intranasal insulin at a dose that effectively raises CSF insulin concentration, 12 whereas peripheral insulin levels were matched between treatment arms by applying a brief intravenous infusion of insulin in the placebo arm to mimic systemic spillover in the intranasal insulin arm. 16 In addition, endogenous secretion of pancreatic hormones was minimized by using a pancreatic clamp. Under these conditions, despite similar peripheral insulin levels, hepatic glucose production was decreased 3 hours after intranasal insulin administration, supporting a role of CNS insulin action in the control of hepatic glucose metabolism. 16 In the current study, using the same intranasal insulin dose (40 IU) and matching of peripheral insulin levels, we assessed the effects of intranasal insulin on TRL particle production in humans under pancreatic clamp conditions. Under this experimental setup, plasma glucose levels tended to be suppressed between 4 and 7 hours. The design of the current study slightly differed from our previous study examining the effect of intranasal insulin on hepatic glucose production 16 in that plasma glucose levels in the present study were not clamped (ie, no dextrose infusion to maintain euglycemia) and that subjects were studied at constant fed state. Plasma FFA levels were also suppressed with intranasal insulin versus placebo at a delayed time, as in previous study. 16 Despite these effects on plasma glucose and FFA, no significant difference in either hepatic or intestinal lipoprotein production or clearance was seen under these experimental conditions. The results of the present study suggest that intranasal insulin at a dose sufficient for regulating hepatic glucose metabolism is ineffective in modulating hepatic and intestinal lipoprotein particle production. Several studies with a single dose of intranasal insulin showed changes in peripheral lipids. For instance, intranasal insulin lowered plasma FFA 17, 18 and decreased hepatic lipid content in humans. 17 It is noted that these studies used a higher intranasal insulin dose (160 IU), which inevitably leads to marked systemic spillover and increased peripheral insulin levels, thus limiting the interpretation of the effects of CNS insulin action. When peripheral insulin levels were matched with intravenous insulin, plasma FFA levels and hepatic lipid content were still lower with intranasal insulin versus placebo. 17 In the current study, circulating FFA levels were lower 3 hours after intranasal insulin than with placebo under pancreatic clamp conditions and with similar peripheral insulin levels, a phenomenon also observed in our previous study. 16 Animal studies have shown modulation of lipid homeostasis by central delivery of insulin, thus insulin infusion into the mediobasal hypothalamus suppressed systemic lipolysis and induced lipogenesis in white adipose tissue in rats. 21 It is intriguing to speculate that the reduction in FFA with intranasal insulin in the current study may imply a brainadipose and brain-liver axis of CNS insulin action in control of peripheral lipid metabolism. Chronic elevation of FFA causes impairment in insulin sensitivity and pancreatic β-cell function. 32 If intranasal insulin lowers plasma FFA levels under normal conditions, it might provide benefits against deterioration of insulin resistance and β-cell failure, ultimately delay of diabetes mellitus onset, and development of cardiometabolic diseases. Although elevation in circulating FFA levels stimulates TRL production in the liver and intestine, 23, 33 the absolute levels of FFA in the current study were low in both study arms during the kinetic study, which may not translate into detectable effects on TRL production under these experimental conditions. It remains to be determined whether intranasal insulin affects TRL production at a later time with prolonged study length. It is worth noting that chronic, 8-week intranasal insulin (40 IU, QID) caused loss of body weight and body fat only in men but not in women. 19 In addition, 4-week intranasal insulin treatment (40 IU, QID) did not alter body weight, body mass index, and hepatic lipid content. 34 In both humans and rats, activation of central K ATP channels mediates CNS regulation of hepatic glucose production, 35, 36 and insulin activates K ATP channels in hypothalamic neurons in rats. 37 CNS insulin action regulates hepatic glucose metabolism by activating several key enzymes involved in liver glucose metabolism, as shown in rodents and dogs. 35, 38, 39 Central glucose metabolism modulates hepatic TRL secretion in rats via glucose conversion to lactate, activation of CNS K ATP channels, and decreased hepatic activity of stearoyl-CoA desaturase-1 in rats. 6 Whether hepatic stearoyl-CoA desaturase-1 is affected by CNS insulin is not known in humans. Although 160 IU intranasal insulin lowered circulating FFA and lipolysis, no significant effects on lipolytic protein expression was observed in subcutaneous adipose tissue of humans. 18 Future studies are needed to examine potential changes in peripheral tissues of enzymes mediating TRL assembly and secretion in response to intranasal insulin administration.
This study has several limitations. Without the infusion of a glycerol tracer, the potential effects of intranasal insulin on triglyceride turnover were not assessed. This study did not examine the possible effects of intranasal insulin on intermediate-density lipoprotein/low-density lipoprotein apoB metabolism. Plasma triglyceride and FFA levels were lower than fasting levels during the kinetic study. This study included only male participants and hence did not evaluate potential sex-specific differences in response to intranasal insulin. Finally, TRL kinetics was examined during a constant fed state. Although intravenous insulin acutely suppressed very-low-density lipoprotein production during both fasted and fed states where very-low-density lipoprotein production rates differ, 22, 23 it remains to be determined whether intranasal insulin affects very-low-density lipoprotein production in the fasted state.
In summary, intranasal insulin at a dose previously shown to raise CSF insulin concentration and modulate hepatic glucose metabolism did not significantly affect TRL secretion by the liver or intestine in healthy humans. The results do not support the practical use of intranasal insulin as a modality for the treatment or prevention of dyslipidemia.
